ReviewMedChemComm2019
Quinolone antibiotics.
Review in MedChemComm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05027893 (Efficacy of the Application of Moxifloxacin and Cefixime in Reduction of Inflammatory Sequelae and Complications After Mandibular Third Molar Surgery), which is not on this map. Cited by 279 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of the Application of Moxifloxacin and Cefixime in Reduction of Inflammatory Sequelae and Complications After Mandibular Third Molar Surgery
Who cites it
279 citing papers in PubMed, 1 synthesis or guideline pooled it, 736 citations in OpenAlex.
- Bactericidal activity of silver nanoparticles in drug-resistant bacteria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Pooled it
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- Integrative Multi-Omics Analysis Suggests a Proteostasis-Translation-Neuroimmune Axis Underlying Moxifloxacin Associated Cognitive Impairment.Molecular neurobiology · 2026Article
- Redefining Fluoroquinolone Antibiotics: Design and Synthesis of Degradable Fluoroquinolones to Reduce Environmental Persistence.ChemSusChem · 2026Article
- A Comprehensive Study of a New Norfloxacin-Niflumate Hydrate: Structural and Physicochemical Properties, Antibiotic Potency, Anti-Inflammatory Effect, and Drug Safety.Molecules (Basel, Switzerland) · 2026Article
- Optimization of gemifloxacin immediate-release tablets using quality by design.Journal of food and drug analysis · 2026Article
- Assessment of Enterococcus faecalis biofilm response to amoxicillin and ciprofloxacin using a dynamic in vitro pharmacokinetic-pharmacodynamic model of catheter-associated urinary tract infection.The Journal of antimicrobial chemotherapy · 2026Article
- Quinolone resistance of Pseudomonas aeruginosa isolated from hospital infections and MexAB-OprM efflux pumps.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
- What's in a Name? Etymology and History of Antibacterials and Antifungals.Open forum infectious diseases · 2026Review
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- Prevalence, resistance profile of ESKAPEE pathogens, and molecular detection of PMQR-associated genes among Levofloxacin-resistant gram-negative ESKAPEE isolates from critically-ill patients.BMC infectious diseases · 2026Article
- Article
- Plasma-Modified ZIF-8-Incorporated PVDF Membrane for Efficient Removal of Antibiotics from Water.ACS omega · 2026Article
- Comparative efficacy of second- and third-generation fluoroquinolone antibiotics against systemic Escherichia coli infection in broiler chickens in Qalyubia Governorate, Egypt.Scientific reports · 2026Article
- Article
- An Updated 16-Year Pharmacovigilance Analysis of Neuropsychiatric Safety Profiles of Ciprofloxacin, Levofloxacin, and Moxifloxacin Using FAERS Data.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Regioselective Iridium-Catalyzed C(7)-H Borylation of FreeACS omega · 2026Article
- A Novel Small Molecule Accelerates Early Persister Regrowth and Potentiates Antibiotic Killing via MdtL-DcrB.Microbial biotechnology · 2026Article
- Efficacy and safety review of tosufloxacin in the treatment of bacterial infection in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
219 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
The quinolone antibiotics arose in the early 1960s, with the first examples possessing a narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the development of new quinolone antibiotics has led to improved analogues with an expanded spectrum and high efficacy. Nowadays, quinolones are widely used for treating a variety of infections. Quinolones are broad-spectrum antibiotics that are active against both Gram-positive and Gram-negative bacteria, including mycobacteria, and anaerobes. They exert their actions by inhibiting bacterial nucleic acid synthesis through disrupting the enzymes topoisomerase IV and DNA gyrase, and by causing breakage of bacterial chromosomes. However, bacteria have acquired resistance to quinolones, similar to other antibacterial agents, due to the overuse of these drugs. Mechanisms contributing to quinolone resistance are mediated by chromosomal mutations and/or plasmid gene uptake that alter the topoisomerase targets, modify the quinolone, and/or reduce drug accumulation by either decreased uptake or increased efflux. This review discusses the development of this class of antibiotics in terms of potency, pharmacokinetics and toxicity, along with the resistance mechanisms which reduce the quinolones' activity against pathogens. Potential strategies for future generations of quinolone antibiotics with enhanced activity against resistant strains are suggested.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.